Arvinas to Participate in Upcoming Virtual Investor Conferences

NEW HAVEN, Conn., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences:

Citi 16th Annual BioPharma Virtual Conference on Thursday, September 9, 2021. John Houston, Ph.D., President and Chief Executive Officer, and Ron Peck, M.D., Chief Medical Officer, will participate in a fireside chat at 9:45 a.m. ET. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021. Sean Cassidy, Chief Financial Officer, and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at 9:20 a.m. ET. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

About ArvinasArvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has three clinical-stage programs: ARV-110 and ARV-766 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

Contacts for ArvinasInvestorsWill O’Connor, Stern Investor Relations [email protected]

MediaKirsten Owens, Arvinas Communications[email protected]

You May Also Be Interested In

• QNB Corp. Announces Pricing of Common Stock Offering
• Statement of B&G Foods Regarding the Competition Bureau Challenge of Pending Sale of Green Giant Canada to Nortera
• Jeff Weniger joins Corgi as Chief Investment Strategist After Nearly a Decade at WisdomTree Asset Management